Published in N Engl J Med on November 30, 1989
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol (1993) 6.36
Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol (1995) 2.34
Expression of processed core protein of hepatitis C virus in mammalian cells. J Virol (1991) 1.91
Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol (1998) 1.46
Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut (1999) 1.44
Serving street-dwelling individuals with psychiatric disabilities: outcomes of a psychiatric rehabilitation clinical trial. Am J Public Health (2000) 1.43
Hepatitis C: progress and problems. Clin Microbiol Rev (1994) 1.37
Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus. Proc Natl Acad Sci U S A (1991) 1.36
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol (2013) 1.35
Automated quantitative determination of hepatitis C virus viremia by reverse transcription-PCR. J Clin Microbiol (1994) 1.29
Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol (2006) 1.28
Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol (2006) 1.25
Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol (2003) 1.25
Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut (2004) 1.17
Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol (1996) 1.13
Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther (2013) 1.09
A rational approach to the management of hepatitis C infection. BMJ (1996) 1.08
Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol (2005) 1.07
Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. EMBO J (1991) 1.06
Nonhepatic manifestations and combined diseases in HCV infection. Dig Dis Sci (1996) 1.06
Identification of a novel gene family that includes the interferon-inducible human genes 6-16 and ISG12. BMC Genomics (2004) 1.04
Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol (2005) 1.00
The management of chronic hepatitis C virus infection. Gut (1995) 0.99
Antiviral therapy: current concepts and practices. Clin Microbiol Rev (1992) 0.96
Infection and infectious diseases. Postgrad Med J (1990) 0.96
Hepatitis C virus and transfusion transmitted liver disease: review. J Clin Pathol (1990) 0.96
Interferon-alpha-induced acute renal allograft rejection. Transplantation (1995) 0.95
Large-population passages of vesicular stomatitis virus in interferon-treated cells select variants of only limited resistance. J Virol (1996) 0.92
Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut (1993) 0.91
Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut (1992) 0.90
Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment. Clin Exp Immunol (1992) 0.90
Sofosbuvir and ABT-450: terminator of hepatitis C virus? World J Gastroenterol (2013) 0.90
Morphine withdrawal enhances hepatitis C virus replicon expression. Am J Pathol (2005) 0.90
Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons. J Virol (1994) 0.89
Sexually transmitted hepatitis: a review. Genitourin Med (1992) 0.88
Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci (1999) 0.88
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol (2007) 0.87
Treatment of chronic hepatitis C with amantadine. Dig Dis Sci (1997) 0.86
Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol (1994) 0.86
Viral markers in the treatment of hepatitis B and C. Gut (1993) 0.86
A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans. Trans Am Clin Climatol Assoc (2000) 0.85
IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol (2012) 0.85
Comparison of a competitive combined reverse transcription-PCR assay with a branched-DNA assay for hepatitis C virus RNA quantitation. J Clin Microbiol (1996) 0.85
Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci (2008) 0.84
Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia. Dig Dis Sci (2002) 0.83
HIV and HCV Medications in End-Stage Renal Disease. Semin Dial (2015) 0.82
Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol (2010) 0.82
Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. Dig Dis Sci (1998) 0.81
Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World J Gastroenterol (2005) 0.81
Can zinc enhance response interferon therapy for patients with HCV-related liver disease? World J Gastroenterol (2012) 0.81
Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. PLoS One (2011) 0.81
Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-alpha) injection in chronic hepatitis C. Clin Exp Immunol (1999) 0.80
Factors influencing treatment efficacy of 24-week combination therapy with interferon alpha-2b plus ribavirin for chronic hepatitis C. Dig Dis Sci (2007) 0.80
CD28-negative CD8-positive cytotoxic T lymphocytes mediate hepatocellular damage in hepatitis C virus infection. J Clin Immunol (2003) 0.80
Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg (1998) 0.80
Effects and outcomes of interferon treatment in Japanese hepatitis C patients. BMC Gastroenterol (2012) 0.79
Chronic non-A, non-B hepatitis: role of hepatitis C virus. Arch Dis Child (1993) 0.79
Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. Antimicrob Agents Chemother (2014) 0.79
Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat (2010) 0.79
High dose interferon treatment in chronic hepatitis C. Gut (1993) 0.78
Initial results with recombinant interferon alfa-2b in patients with chronic hepatitis C: the United States experience. Gut (1993) 0.78
Hemodynamics in the portal vein evaluated by pulse wave Doppler ultrasonography in patients with chronic hepatitis C treated with interferon. World J Gastroenterol (2005) 0.77
Is laparoscopy an advantage in the diagnosis of cirrhosis in chronic hepatitis C virus infection? World J Gastroenterol (2003) 0.77
IgG1 anti-P2 as a marker of response to interferon in patients with chronic hepatitis C. Clin Exp Immunol (2001) 0.77
Improvement of molar ratio of branched-chain amino acids to tyrosine (BTR) associated with liver fibrosis in chronic hepatitis C patients treated with interferon-alpha. Dig Dis Sci (1999) 0.77
Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. Can J Gastroenterol (2006) 0.77
The Effect Of Long Term and High Dose Interferon Treatment In Chronic Hepatitis C. Pathol Oncol Res (1996) 0.77
An analysis of risk factors for developing Hepatocellular carcinoma in a group of Hepatitis C patients with stage 3 fibrosis following interferon therapy. Cancer Inform (2008) 0.77
Predictive factors for beneficial response to interferon-alfa therapy in chronic hepatitis C. Korean J Intern Med (1995) 0.77
Efficacy and tolerability of combination therapy with interferon-alfa plus ribavirin in patients with chronic hepatitis C virus infection: a single-center study in relapsers and nonresponders to previous treatment with high-dose interferon-alfa monotherapy. Curr Ther Res Clin Exp (2003) 0.77
Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2. World J Gastroenterol (2006) 0.76
Hepatic histology of patients with HIV infection and chronic hepatitis C treated with interferon. J Clin Pathol (1997) 0.76
Gastroenterology. Postgrad Med J (1990) 0.76
Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol (2015) 0.76
Randomized trial assessing gastric emptying in patients with chronic hepatitis C during interferon-alpha or -beta therapy and effect of cisapride. Dig Dis Sci (2002) 0.75
Interferon alfa for chronic hepatitis C in haemophiliacs. Gut (1993) 0.75
Evaluated outcomes in patients with Chronic Hepatitis C. Gastroenterol Hepatol Bed Bench (2013) 0.75
Non-A, non-B hepatitis. West J Med (1990) 0.75
Amantadine therapy for chronic hepatitis C. J Gen Intern Med (2004) 0.75
Parenterally acquired non-A non-B hepatitis ten years on: advances in diagnosis and therapy. Postgrad Med J (1990) 0.75
Interferon alpha therapy in patients with chronic type C hepatitis: changes of serum ALT, anti-HCV & HCV-RNA. Korean J Intern Med (1992) 0.75
Hepatology. Postgrad Med J (1991) 0.75
Hepatitis C virus. A review. West J Med (1991) 0.75
Hepatitis C: Recent advances. Can J Infect Dis (1993) 0.75
Hepatitis C infection after blood product transfusion. Arch Dis Child (1996) 0.75
Treatment of chronic hepatitis C with recombinant interferon alfa. West J Med (1992) 0.75
Impact of hepatitis C status on 20-year mortality of patients with substance use disorders. Addict Sci Clin Pract (2015) 0.75
Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis. Gut (1993) 0.75
Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2015) 0.75
Viral hepatitis. Gut (1991) 0.75
Constitutively Active MAVS Inhibits HIV-1 Replication via Type I Interferon Secretion and Induction of HIV-1 Restriction Factors. PLoS One (2016) 0.75
Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial. J Gastroenterol (1997) 0.75
Two years versus six months of interferon therapy for chronic hepatitis C. Dig Dis Sci (1996) 0.75
Occurrence of hepatocellular carcinoma in chronic viral hepatitis. Cancer Chemother Pharmacol (1994) 0.75
Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis. Dig Dis Sci (1997) 0.75
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol (1986) 10.84
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet (1993) 8.54
Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology (1994) 7.89
The repair of double-strand breaks in the nuclear DNA of Saccharomyces cerevisiae and its genetic control. Mol Gen Genet (1976) 6.89
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med (2000) 5.27
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med (1998) 4.99
Nucleotide sequence of the tetM tetracycline resistance determinant of the streptococcal conjugative shuttle transposon Tn1545. Nucleic Acids Res (1986) 4.47
Antibody to hepatitis-B-virus core in man. Lancet (1973) 4.24
Management of hepatitis B: 2000--summary of a workshop. Gastroenterology (2001) 4.17
On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med (1975) 4.11
HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science (1982) 4.07
Carbonated soft drink consumption and bone mineral density in adolescence: the Northern Ireland Young Hearts project. J Bone Miner Res (2003) 3.84
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology (2000) 3.42
Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry (1995) 3.30
An association between viral genes and human oncogenic alterations: the adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1. Nat Med (1999) 3.27
Postnatal depression. BMJ (1998) 3.24
Post-partum depression and the mother-infant relationship in a South African peri-urban settlement. Br J Psychiatry (1999) 3.13
Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell (2001) 3.05
Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med (1990) 2.99
The impact of overtime and long work hours on occupational injuries and illnesses: new evidence from the United States. Occup Environ Med (2005) 2.99
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med (1986) 2.85
Management of traumatic intracranial haematoma. Br Med J (Clin Res Ed) (1982) 2.79
Dynamic actin-based epithelial adhesion and cell matching during Drosophila dorsal closure. Curr Biol (2000) 2.78
Course and recurrence of postnatal depression. Evidence for the specificity of the diagnostic concept. Br J Psychiatry (1995) 2.77
X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol (2000) 2.71
Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med (1989) 2.69
Growing differences between Medicare beneficiaries with and without drug coverage. Health Aff (Millwood) (2001) 2.68
Mechanisms of epithelial fusion and repair. Nat Cell Biol (2001) 2.63
A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. Am J Gastroenterol (2005) 2.63
Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Differentiation (1997) 2.58
Failure of silicone gel breast implants: analysis of literature data for 1652 explanted prostheses. Plast Reconstr Surg (1997) 2.56
Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon. EMBO J (1984) 2.55
Long-term therapy of chronic hepatitis B with lamivudine. Hepatology (2000) 2.49
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 2.49
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med (1989) 2.42
Experimental infection of chimpanzees with hepatitis A virus. J Infect Dis (1975) 2.41
Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther (2013) 2.38
The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. Gut (1997) 2.35
Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature (1995) 2.33
Genotypic analysis of hepatitis C virus in American patients. Hepatology (1994) 2.33
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.31
Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med (1978) 2.30
Local inflammatory responses following bronchial endotoxin instillation in humans. Am J Respir Crit Care Med (2001) 2.28
The infant's role in mother-infant communications. J Child Lang (1986) 2.28
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology (1991) 2.25
Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry (1994) 2.24
Measurements of iron status in patients with chronic hepatitis. Gastroenterology (1992) 2.22
Safeguards for research using large scale DNA collections. BMJ (2000) 2.22
Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology (1988) 2.20
Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther (2014) 2.19
env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area. J Virol (2000) 2.17
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
An immunohistochemical method that differentiates Cryptococcus neoformans varieties and serotypes in formalin-fixed paraffin-embedded tissues. Med Mycol (2001) 2.16
Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology (1991) 2.15
Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat (2013) 2.15
Putting ion channels to work: mechanoelectrical transduction, adaptation, and amplification by hair cells. Proc Natl Acad Sci U S A (2000) 2.15
Sequencing the erbA gene of avian erythroblastosis virus reveals a new type of oncogene. Science (1984) 2.12
Healing of incisional wounds in the embryonic chick wing bud: characterization of the actin purse-string and demonstration of a requirement for Rho activation. J Cell Biol (1996) 2.12
A selective impairment in the processing of sad and fearful expressions in children with psychopathic tendencies. J Abnorm Child Psychol (2001) 2.09
Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest (1996) 2.04
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg (1995) 2.03
Unexpected Ebola virus in a tertiary setting: clinical and epidemiologic aspects. Crit Care Med (2000) 2.03
Absence of hepatitis C viral RNA from saliva and semen of patients with chronic hepatitis C. Gastroenterology (1992) 1.99
Antibody to hepatitis B core antigen. A sensitive indicator of hepatitis B virus replication. N Engl J Med (1974) 1.98
Hypodontia due to ectodermal dysplasia: rehabilitation with very early dental implants. Rev Stomatol Chir Maxillofac Chir Orale (2013) 1.97
[Hypodontia due to ectodermal dysplasia: rehabilitation with very early dental implants]. Rev Stomatol Chir Maxillofac Chir Orale (2013) 1.97
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology (2000) 1.97
Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med (1981) 1.96
Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology (1987) 1.94
Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci (2000) 1.92
Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med (1991) 1.92
Viral hepatitis, type B, DNA polymerase activity and antibody to hepatitis B core antigen. N Engl J Med (1974) 1.92
Long-term survival after retransplantation of the liver. Ann Surg (1997) 1.91
Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology (1988) 1.91
Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol (1997) 1.91
Epidemiology of thrombocytopenia in HIV infection. Eur J Haematol (1992) 1.88
Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest (1989) 1.87
Effects of postnatal depression on children's adjustment to school. Teacher's reports. Br J Psychiatry (1998) 1.85
Hepatitis C viral RNA in serum of patients with chronic non-A, non-B hepatitis: detection by the polymerase chain reaction using multiple primer sets. Hepatology (1991) 1.82
Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther (2003) 1.82
Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet (1978) 1.82
Identification of grandchildless loci whose products are required for normal germ-line development in the nematode Caenorhabditis elegans. Genetics (1991) 1.81
Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther (2012) 1.81
Transforming viruses directly reduce the cellular growth requirement for a platelet derived growth factor. J Cell Physiol (1978) 1.79
What level of physical activity protects against premature cardiovascular death? The Caerphilly study. Heart (2003) 1.79
Biliary atresia: current concepts and research directions. Summary of a symposium. Hepatology (1996) 1.78
Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest (1991) 1.77
Validation of a model of colon cancer progression. J Pathol (2000) 1.76
Macrophage recruitment during limb development and wound healing in the embryonic and foetal mouse. J Cell Sci (1994) 1.74
99mTc-tagged chicken liver as a marker of solid food in the human stomach. Am J Dig Dis (1976) 1.74
Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens (1996) 1.73
MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene (2012) 1.73